A meta-analysis including small randomized controlled trials conducted in patients with NAFLD found that microbial therapies (probiotics, prebiotics, and synbiotics—(PPS)) significantly reduced body mass index and alanine transaminase (ALT) levels but not markers of inflammation (tumor necrosis factor-alpha (TNF-α) and C-reactive protein (CRP)) [22]. The gene discussed is CRP; the disease is metabolic dysfunction-associated steatotic liver disease.